

Summary of status of development and availability of variant¹ influenza A(H3) candidate vaccine viruses*

* Antigenic and genetic analyses are performed by the WHO Collaborating Centres of the Global Influenza Surveillance and Response System (GISRS). Unless otherwise indicated all candidate vaccine viruses posted on this table have passed two-way haemagglutination inhibition (HI) test.

[National or Regional control authorities approve the composition and formulation of vaccines used in each country](#)

28 September 2017

Candidate vaccine viruses

Antigenic prototype*	Candidate vaccine virus	Type of virus or reassortant	Developing institute	Available from
A/Minnesota/11/2010 (H3N2)v	NYMC X-203	Classical	NYMC, USA	CDC, USA NYMC, USA
	NYMC X-203A	Classical	NYMC, USA	CDC, USA NYMC, USA
A/Indiana/10/2011 (H3N2)v	NYMC X-213	Classical	NYMC, USA	CDC, USA NYMC, USA

Candidate vaccine viruses in preparation

Antigenic prototype	Type of virus or reassortant	Developing Institute	Available from
A/Ohio/13/2017 (H3N2)v	Reverse genetics	CDC, USA	pending

* "Antigenic prototype" indicates that the antigenic characteristics of the CVV(s) in the table are antigenically like the virus listed.

Institutes contact details for candidate vaccine viruses orders/information:

CDC: dwentworth@cdc.gov (Subject: CVV request)

NIBSC: standards@nibsc.org or enquiries@nibsc.org

NYMC: doris_bucher@nymc.edu

For general enquiries, please contact gisrs-whohq@who.int

For other candidate vaccine viruses and potency testing reagents, please go to

<http://www.who.int/influenza/vaccines/virus/en/>

¹ Joint FAO, OIE, WHO announcement of the standardization of terminology for the variant A(H3N2) virus recently infecting humans at http://www.who.int/influenza/gisrs_laboratory/terminology_ah3n2v/